Last reviewed 2026-05-19 · How we verify

PF-05221304 Formulation B

Pfizer · Phase 1 active Small molecule ✓ Verified May 2026

PF-05221304 Formulation B is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.

PF-05221304 Formulation B is a small molecule inhibitor of the enzyme Acetyl-CoA carboxylase. It is being studied in a clinical trial to compare its bioavailability with another formulation, PF-05221304 Formulation A, in healthy adults.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PF-05221304 Formulation B
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-05221304 Formulation B CI brief — competitive landscape report
PF-05221304 Formulation B updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about PF-05221304 Formulation B

What is PF-05221304 Formulation B?

PF-05221304 Formulation B is a Small molecule drug developed by Pfizer.

Who makes PF-05221304 Formulation B?

PF-05221304 Formulation B is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What development phase is PF-05221304 Formulation B in?

PF-05221304 Formulation B is in Phase 1.

Manufacturer: Pfizer — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing